Intellipharmaceutics Announces Second Quarter 2021 Results
ACCESSWIRE
16 Jul 2021, 06:55 GMT+10
TORONTO, ON / ACCESSWIRE / July 15, 2021 / Intellipharmaceutics International Inc. (OTCQB:IPCIF)(TSX:IPCI) ( Intellipharmaceutics or the Company ), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today reported the results of operations for the three and six months ended May 31, 2021. All dollar amounts referenced herein are in United States dollars unless otherwise noted.
Effective May 5, 2021 our exclusive license agreements with Tris Pharma, Inc. for generic Seroquel XR®, generic Pristiq® and generic Effexor XR® were mutually terminated. Products were never supplied nor distributed under the licenses. Termination of the exclusive agreements may provide opportunity for the Company to explore options of supplying the products to multiple sources on non-exclusiv
Intellipharmaceutics Announces Second Quarter 2021 Results
newjerseytelegraph.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from newjerseytelegraph.com Daily Mail and Mail on Sunday newspapers.
Intellipharmaceutics International Inc : Intellipharmaceutics Announces Second Quarter 2021 Results
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
Intellipharmaceutics Announces Second Quarter 2021 Results
apnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from apnews.com Daily Mail and Mail on Sunday newspapers.
Stock Wars: AstraZeneca Vs. Pfizer
Benzinga’s Stock Wars series matches up two leaders in a major industry sector, with the goal of letting readers decide which company is the better investment.
In this week’s installment, we take a look at two pharmaceutical giants at the forefront of the COVID-19 vaccine development:
AstraZeneca plc (NASDAQ:AZN) and
Pfizer Inc. (NYSE:PFE).
The AstraZeneca Experience: AstraZeneca was founded in 1999 through the merger of the Swedish Astra AB, which dated back to 1913, and Britain’s Zeneca Group plc, with the merged company setting up its headquarters in Britain.
During the COVID-19 crisis, AstraZeneca teamed with scientists at Oxford University to create a vaccine to stop the spread of the pandemic. The first doses of the vaccine given to patients outside of clinical tests took place in the U.K. in January, and one month later the World Health Organization issued interim guidance and recommended the vaccine for all adults.